생화학분자생물학회

	Dong-oh Seo( seo.biome@gmail.com )
	2020-present	Instructor, Department of Neurology, Washington University in St. Louis, Missouri, USA
	2018-2020	Postdoctoral Research Associate, Department of Neurology, Washington University in St. Louis, Missouri, USA
	2015-2018	Postdoctoral Research Associate, Department of Anesthesiology, Washington University in St. Louis, Missouri, USA
	2009-2015	Ph.D in Behavioral Neuroscience, The University of Texas at Austin, Texas, USA

Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies

Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disease. Despite tremendous research efforts to understand this complex disease, the exact pathophysiology of the disease is not completely clear. Recently, anti-Aβ antibodies have been shown to remove amyloid from the brain and slow the clinical progression of mild dementia by ~30%. However, exploring alternative strategies is crucial to understanding and developing more effective therapeutic interventions. In recent years, the microbiota-gut-brain axis has received significant attention in the AD field. Numerous studies have suggested that alterations in the gut microbiota composition are associated with the progression of AD, and several underlying mechanisms have been proposed. However, studies in this area are still in their infancy, and many aspects of this field are just beginning to be explored and understood. Gaining a deeper understanding of the intricate interactions and signaling pathways involved in the microbiota-AD interaction is crucial for optimizing therapeutic strategies targeting gut microbiota to positively impact AD. In this review, we aim to summarize the current understanding of the microbiota-gut-brain axis in AD. We will discuss the existing evidence regarding the role of gut microbiota in AD pathogenesis, suggested underlying mechanisms, biological factors influencing the microbiome-gut-brain axis in AD, and remaining questions in the field. Last, we will discuss potential therapeutic approaches to recondition the community of gut microbiota to alleviate disease progression. An ongoing exploration of the gut-brain axis and the development of microbiota-based therapies hold the potential for advancing AD management in the future.

Exp Mol Med. 2024 Feb;56(1):86-94. doi: 10.1038/s12276-023-01146-2
https://pubmed.ncbi.nlm.nih.gov/38172602/